Cytek Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 193.39 million compared to USD 164.04 million a year ago. Net loss was USD 11.33 million compared to net income of USD 2.48 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +2.31% | -2.70% | -36.84% |
Mar. 20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
Mar. 19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.84% | 756M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023